1991
High‐dose cisplatin plus dacarbazine in the treatment of metastatic melanoma
Murren J, Derosa W, Durivage H, Davis C, Makuch R, Portlock C. High‐dose cisplatin plus dacarbazine in the treatment of metastatic melanoma. Cancer 1991, 67: 1514-1517. PMID: 2001539, DOI: 10.1002/1097-0142(19910315)67:6<1514::aid-cncr2820670609>3.0.co;2-q.Peer-Reviewed Original Research
1986
Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer.
Ihde D, Deisseroth A, Lichter A, Bunn P, Carney D, Cohen M, Veach S, Makuch R, Johnston-Early A, Abrams R. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. Journal Of Clinical Oncology 1986, 4: 1443-54. PMID: 3020181, DOI: 10.1200/jco.1986.4.10.1443.Peer-Reviewed Original ResearchConceptsExtensive-stage SCLC patientsProphylactic cranial irradiationComplete responseAutologous bone marrowPartial responseSCLC patientsModality therapyTumor regressionMedical conditionsExtensive-stage small-cell lung cancer patientsExtensive-stage small-cell lung cancerSmall cell lung cancer patientsAutologous bone marrow infusionMajor non-hematologic toxicitySmall cell lung cancerExtensive-stage patientsNon-hematologic toxicitiesWeeks of cyclophosphamideWeeks of vincristineBone marrow infusionGood medical conditionPoor medical conditionLung cancer patientsBetter tumor regressionCranial irradiationCombined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up.
Winkler C, Sausville E, Ihde D, Fischmann A, Schechter G, Kumar P, Nibhanupdi J, Minna J, Makuch R, Eddy J. Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up. Journal Of Clinical Oncology 1986, 4: 1094-100. PMID: 3088220, DOI: 10.1200/jco.1986.4.7.1094.Peer-Reviewed Original ResearchConceptsTotal skin electron beam irradiationStage I patientsCutaneous T-cell lymphomaDisease-free survivalT-cell lymphomaI patientsStage IIComplete responseModality treatmentCell lymphomaStage IMedian disease-free survivalDisease-free survivorsThree-drug regimensCombined modality treatmentAdvanced-stage patientsOverall response rateOral corticosteroidsAdvanced diseaseSystemic chemotherapyProtocol treatmentTopical therapyStage patientsCR rateSimultaneous chemotherapy
1984
Predictive factors for tumor response to preoperative chemotherapy in patients with head and neck squamous carcinoma: The head and neck contracts program
Wolf G, Makuch R, Baker S. Predictive factors for tumor response to preoperative chemotherapy in patients with head and neck squamous carcinoma: The head and neck contracts program. Cancer 1984, 54: 2869-2877. PMID: 6208993, DOI: 10.1002/1097-0142(19841215)54:12<2869::aid-cncr2820541210>3.0.co;2-n.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaTumor responsePartial responsePreoperative chemotherapyComplete responseResponse rateTumor characteristicsCell carcinomaHigh tumor response ratesNeck squamous cell carcinomaNodal response ratesResectable stage IIIPatient performance statusPrimary tumor responseTumor response rateNational Cancer Institute trialsNeck squamous carcinomaVariety of patientsLarynx/Preoperative cisplatinChemotherapy regimenIntensive chemotherapyUntreated patientsAdvanced headPerformance status
1983
Treatment of extensive stage small cell bronchogenic carcinoma Effects of variation in intensity of induction chemotherapy
Brower M, Ihde D, Johnston-Early A, Bunn P, Cohen M, Carney D, Makuch R, Matthews M, Radice P, Minna J. Treatment of extensive stage small cell bronchogenic carcinoma Effects of variation in intensity of induction chemotherapy. The American Journal Of Medicine 1983, 75: 993-1000. PMID: 6316784, DOI: 10.1016/0002-9343(83)90880-x.Peer-Reviewed Original ResearchConceptsHigh-intensity groupSmall cell bronchogenic carcinomaHigh-intensity therapyCell bronchogenic carcinomaInduction chemotherapyInduction courseInduction deathBronchogenic carcinomaDay 1Reversible congestive heart failureModerate-intensity therapyOverall median survivalCongestive heart failureSevere peripheral neuropathyModerate-intensity groupEvaluable patientsComplete remissionInduction therapyInfectious complicationsPartial remissionMedian survivalUntreated patientsComplete responseHeart failurePeripheral neuropathyRole of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer Potential benefit restricted to patients with complete response
Rosen S, Makuch R, Lichter A, Ihde D, Matthews M, Minna J, Glatstein E, Bunn P. Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer Potential benefit restricted to patients with complete response. The American Journal Of Medicine 1983, 74: 615-624. PMID: 6301274, DOI: 10.1016/0002-9343(83)91019-7.Peer-Reviewed Original ResearchConceptsCentral nervous system metastasesProphylactic cranial irradiationNervous system metastasesCranial irradiationComplete responsePrognostic featuresSystemic therapyCentral nervous system relapseSmall cell lung cancerInvolvement of liverPercent of patientsNervous system relapseSystemic combination chemotherapySubset of patientsTwo-year survivalCell lung cancerStage of diseaseCentral nervous systemNational Cancer InstituteChest irradiationComplete remissionEpidural metastasesOverall survivalCombination chemotherapyIntracerebral metastases
1982
Carcinomatous Leptomeningitis in Small Cell Lung Cancer
ROSEN S, AISNER J, MAKUCH R, MATTHEWS M, IHDE D, WHITACRE M, GLATSTEIN E, WIERNIK P, LICHTER A, BUNN P. Carcinomatous Leptomeningitis in Small Cell Lung Cancer. Medicine 1982, 61: 45. PMID: 6276648, DOI: 10.1097/00005792-198201000-00005.Peer-Reviewed Original ResearchConceptsClinical courseSystemic diseaseSpinal cordUnivariate log-rank analysisSmall cell lung cancerProgressive systemic diseaseLog-rank analysisPatient's clinical courseSpinal cord lesionsCell lung cancerVirchow-Robin spacesLife-table analysisCNS metastasesComplete respondersExtensive diseaseIntrathecal chemotherapyLiver metastasesMedian survivalSystemic therapyComplete responseCord lesionsIntracerebral metastasesAutopsy featuresDiffuse involvementSole manifestation
1981
Preoperative Cisplatin and Bleomycin Therapy in Head and Neck Squamous Carcinoma: Prognostic Factors for Tumor Response
Baker S, Makuch R, Wolf G. Preoperative Cisplatin and Bleomycin Therapy in Head and Neck Squamous Carcinoma: Prognostic Factors for Tumor Response. JAMA Otolaryngology - Head & Neck Surgery 1981, 107: 683-689. PMID: 6170283, DOI: 10.1001/archotol.1981.00790470031008.Peer-Reviewed Original ResearchConceptsPrimary tumorInduction chemotherapyPreoperative cisplatinPartial responseComplete responseRegional adenopathyResectable stage IIISquamous cell carcinomaNational Cancer Institute trialsNeck squamous carcinomaPretreatment patientsPrognostic factorsBleomycin therapyNeck nodesSquamous carcinomaTumor characteristicsCell carcinomaPrognostic indicatorTumor responseRegional nodesBleomycin sulfateOral cavityStage IIIResponse rateChemotherapy
1979
Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma.
Cohen M, Ihde D, Bunn P, Fossieck B, Matthews M, Shackney S, Johnston-Early A, Makuch R, Minna J. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Journal Of The National Cancer Institute 1979, 63: 163-70. PMID: 221114.Peer-Reviewed Original ResearchConceptsSmall cell bronchogenic carcinomaResistant drug combinationsCell bronchogenic carcinomaCR rateCombination chemotherapyComplete responseBronchogenic carcinomaDrug combinationsExtensive disease patientsLimited disease patientsProtocol-eligible patientsHigh-dose cyclophosphamideBrain radiation therapyDisease-free survivalComplete respondersDrug regimensProlong survivalInitial treatmentRadiation therapyPatientsVP-16ChemotherapyCarcinomaSequential useMonths